Company Profile
Alterity Therapeutics Limited is provides research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease.
The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy
Biomarkers of progression in multiple system atrophy. It also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases.
Formerly known as Prana Biotechnology Limited, the company rebranded as Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.